FOLH1 and adrenal cortex carcinoma: Although the available evidence is still weak, and the studies screened employed different methods for estimating the detection rate, all the scholars assessing the accuracy of PET/CT with PSMA-targeting radiopharmaceuticals in ACC patients found excellent results in newly diagnosed patients, as well as those who had been previously treated and had undergone disease restaging [14,15,16,17,18,19].